Literature DB >> 22492044

Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension.

Carmen Capone1, Giuseppe Faraco, Jeffrey R Peterson, Christal Coleman, Josef Anrather, Teresa A Milner, Virginia M Pickel, Robin L Davisson, Costantino Iadecola.   

Abstract

Hypertension, a powerful risk factor for stroke and dementia, has damaging effects on the brain and its vessels. In particular, hypertension alters vital cerebrovascular control mechanisms linking neural activity to cerebral perfusion. In experimental models of slow-developing hypertension, free radical signaling in the subfornical organ (SFO), one of the forebrain circumventricular organs, is critical for the hormonal release and sympathetic activation driving the elevation in arterial pressure. However, the contribution of this central mechanism to the cerebrovascular alterations induced by hypertension remains uncertain. We tested the hypothesis that free radical production in the SFO is involved in the alterations in cerebrovascular regulation produced by hypertension. In a mouse model of gradual hypertension induced by chronic administration of subpressor doses of angiotensin II (AngII), suppression of free radicals in the SFO by overexpression of CuZn-superoxide dismutase (CuZnSOD) prevented the alteration in neurovascular coupling and endothelium-dependent responses in somatosensory cortex induced by hypertension. The SFO mediates the dysfunction via two signaling pathways. One involves SFO-dependent activation of the paraventricular hypothalamic nucleus, elevations in plasma vasopressin, upregulation of endothelin-1 in cerebral resistance arterioles and activation of endothelin type A receptors. The other pathway depends on activation of cerebrovascular AngII type 1 (AT1) receptors by AngII. Both pathways mediate vasomotor dysfunction by inducing vascular oxidative stress. The findings implicate for the first time the SFO and its efferent hypothalamic pathways in the cerebrovascular alterations induced by AngII, and identify vasopressin and endothelin-1 as potential therapeutic targets to counteract the devastating effects of hypertension on the brain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492044      PMCID: PMC3328774          DOI: 10.1523/JNEUROSCI.6262-11.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

1.  A slowly developing pressor response to small concentrations of angiotensin. Its bearing on the pathogenesis of chronic renal hypertension.

Authors:  C J DICKINSON; J R LAWRENCE
Journal:  Lancet       Date:  1963-06-22       Impact factor: 79.321

2.  Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats.

Authors:  P L Tharaux; C Chatziantoniou; D Casellas; L Fouassier; R Ardaillou; J C Dussaule
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

3.  Effect of endogenous vasopressin on blood flow to choroid plexus during hypoxia and intracranial hypertension.

Authors:  F M Faraci; D Kinzenbaw; D D Heistad
Journal:  Am J Physiol       Date:  1994-02

4.  SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein.

Authors:  C Iadecola; F Zhang; K Niwa; C Eckman; S K Turner; E Fischer; S Younkin; D R Borchelt; K K Hsiao; G A Carlson
Journal:  Nat Neurosci       Date:  1999-02       Impact factor: 24.884

5.  Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals.

Authors:  Ken Kazama; Josef Anrather; Ping Zhou; Helene Girouard; Kelly Frys; Teresa A Milner; Costantino Iadecola
Journal:  Circ Res       Date:  2004-10-21       Impact factor: 17.367

6.  Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients.

Authors:  K Matsushita; Y Kuriyama; K Nagatsuka; M Nakamura; T Sawada; T Omae
Journal:  Hypertension       Date:  1994-05       Impact factor: 10.190

Review 7.  Oxidative stress and hypertension.

Authors:  David G Harrison; Maria Carolina Gongora
Journal:  Med Clin North Am       Date:  2009-05       Impact factor: 5.456

8.  Intravenous angiotensin II induces Fos-immunoreactivity in circumventricular organs of the lamina terminalis.

Authors:  M J McKinley; E Badoer; B J Oldfield
Journal:  Brain Res       Date:  1992-10-30       Impact factor: 3.252

9.  White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates.

Authors:  E Englund; A Brun; C Alling
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

10.  Optimization of differential immunogold-silver and peroxidase labeling with maintenance of ultrastructure in brain sections before plastic embedding.

Authors:  J Chan; C Aoki; V M Pickel
Journal:  J Neurosci Methods       Date:  1990-08       Impact factor: 2.390

View more
  53 in total

Review 1.  Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease.

Authors:  Jasenka Zubcevic; Monica M Santisteban; Teresa Pitts; David M Baekey; Pablo D Perez; Donald C Bolser; Marcelo Febo; Mohan K Raizada
Journal:  Hypertension       Date:  2014-03-31       Impact factor: 10.190

2.  Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation.

Authors:  Giuseppe Faraco; Ana Moraga; Jamie Moore; Joseph Anrather; Virginia M Pickel; Costantino Iadecola
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

3.  Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in β-amyloid generation and Alzheimer's disease.

Authors:  Anna Csiszar; Zsuzsanna Tucsek; Peter Toth; Danuta Sosnowska; Tripti Gautam; Akos Koller; Ferenc Deak; William E Sonntag; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-16       Impact factor: 4.733

4.  Alterations in the subcellular distribution of NADPH oxidase p47(phox) in hypothalamic paraventricular neurons following slow-pressor angiotensin II hypertension in female mice with accelerated ovarian failure.

Authors:  Tracey A Van Kempen; Ankita Narayan; Elizabeth M Waters; Jose Marques-Lopes; Costantino Iadecola; Michael J Glass; Virginia M Pickel; Teresa A Milner
Journal:  J Comp Neurol       Date:  2015-12-23       Impact factor: 3.215

5.  Mineralocorticoid and AT1 receptors in the paraventricular nucleus contribute to sympathetic hyperactivity and cardiac dysfunction in rats post myocardial infarct.

Authors:  Bing S Huang; Aidong Chen; Monir Ahmad; Hong-Wei Wang; Frans H H Leenen
Journal:  J Physiol       Date:  2014-06-20       Impact factor: 5.182

6.  Hypertension-induced synapse loss and impairment in synaptic plasticity in the mouse hippocampus mimics the aging phenotype: implications for the pathogenesis of vascular cognitive impairment.

Authors:  Zsuzsanna Tucsek; M Noa Valcarcel-Ares; Stefano Tarantini; Andriy Yabluchanskiy; Gábor Fülöp; Tripti Gautam; Albert Orock; Anna Csiszar; Ferenc Deak; Zoltan Ungvari
Journal:  Geroscience       Date:  2017-06-29       Impact factor: 7.713

Review 7.  Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease.

Authors:  Kassandra Kisler; Amy R Nelson; Axel Montagne; Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2017-05-18       Impact factor: 34.870

8.  Neurovascular regulation in the ischemic brain.

Authors:  Katherine Jackman; Costantino Iadecola
Journal:  Antioxid Redox Signal       Date:  2015-01-10       Impact factor: 8.401

Review 9.  Rostral Ventrolateral Medulla and Hypertension.

Authors:  Patrice G Guyenet; Ruth L Stornetta; Benjamin B Holloway; George M P R Souza; Stephen B G Abbott
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

10.  A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Authors:  Meredith Hay; Robin Polt; Michael L Heien; Todd W Vanderah; Tally M Largent-Milnes; Kathleen Rodgers; Torsten Falk; Mitchell J Bartlett; Kristian P Doyle; John P Konhilas
Journal:  J Pharmacol Exp Ther       Date:  2019-02-01       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.